Arvinas (ARVN) Capital Expenditures (2017 - 2026)
Arvinas' (ARVN) quarterly Capital Expenditures came in at $1.3 million in Q1 2026, up 225.0% year-on-year from $400000.0 in Q1 2025, and up 192.86% quarter-over-quarter from -$1.4 million in Q4 2025.
Arvinas (ARVN) Capital Expenditures (2017 - 2026) Analysis & Trends
Arvinas' Capital Expenditures history runs 10 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 225.0% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 45.45% decrease from a year earlier, with the FY2025 full-year figure at $300000.0, down 83.33% from the prior year.
- Capital Expenditures grew to $1.3 million in Q1 2026 per ARVN's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.1 million in Q1 2022 and bottomed at -$1.6 million in Q2 2022.
- The 5-year median for Capital Expenditures is $500000.0 (2023), against an average of $400000.0.
- Across the five-year window, Capital Expenditures soared 650.0% in 2023 and tumbled 566.67% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at -$200000.0 in 2022, then jumped by 150.0% to $100000.0 in 2023, then soared by 200.0% to $300000.0 in 2024, then tumbled by 566.67% to -$1.4 million in 2025, then surged by 192.86% to $1.3 million in 2026.
- Per Business Quant, the three latest ARVN Capital Expenditures figures stand at $1.3 million (Q1 2026), -$1.4 million (Q4 2025), and $100000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | -1.40 Mn |
| Dec 31, 2025 | -1.40 Mn |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.10 Mn |